Syrian hamster tumor model to study oncolytic Ad5-based vectors
- PMID: 21948468
- DOI: 10.1007/978-1-61779-340-0_4
Syrian hamster tumor model to study oncolytic Ad5-based vectors
Abstract
Oncolytic (replicating) adenovirus (Ad) vectors are emerging as a promising form of a cancer therapy agent. There has been a need for an appropriate animal model to study oncolytic Ad since human Ad -replication is usually species specific. We have shown that Syrian (golden) hamsters are an appropriate animal model to study human Ad5-based vectors. Syrian hamsters are immunocompetent, and they allow human Ad5 replication in normal tissues as well as in Syrian hamster cancer cells. The development of the Syrian hamster as a model to study oncolytic Ad vectors has opened avenues to explore the role of host immune response and preexisting immunity in Ad vector efficacy and toxicity/biodistribution following Ad vector administration. Since most of the normal tissues in the Syrian hamster are permissive for human Ad5 replication, Ad vectors can be studied in the context of orthotopic cancer model developed in Syrian hamsters.
Similar articles
-
Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.J Virol. 2009 Mar;83(5):2130-9. doi: 10.1128/JVI.02127-08. Epub 2008 Dec 10. J Virol. 2009. PMID: 19073718 Free PMC article.
-
Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors.Cancer Res. 2006 Feb 1;66(3):1270-6. doi: 10.1158/0008-5472.CAN-05-3497. Cancer Res. 2006. PMID: 16452178
-
Chapter three--Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds.Adv Cancer Res. 2012;115:69-92. doi: 10.1016/B978-0-12-398342-8.00003-3. Adv Cancer Res. 2012. PMID: 23021242 Review.
-
Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors.Methods Mol Med. 2007;130:169-83. doi: 10.1385/1-59745-166-5:169. Methods Mol Med. 2007. PMID: 17401172
-
Oncolytic adenoviral therapy for glioblastoma multiforme.Neurosurg Focus. 2006 Apr 15;20(4):E19. Neurosurg Focus. 2006. PMID: 16709024 Review.
Cited by
-
A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses.J Virol. 2012 Jun;86(11):6286-302. doi: 10.1128/JVI.00205-12. Epub 2012 Mar 28. J Virol. 2012. PMID: 22457526 Free PMC article.
-
Target expression of Staphylococcus enterotoxin A from an oncolytic adenovirus suppresses mouse bladder tumor growth and recruits CD3+ T cell.Tumour Biol. 2013 Oct;34(5):2863-9. doi: 10.1007/s13277-013-0847-3. Epub 2013 May 19. Tumour Biol. 2013. PMID: 23686803
-
Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters.Cancer Gene Ther. 2014 Apr;21(4):171-8. doi: 10.1038/cgt.2014.13. Epub 2014 Apr 11. Cancer Gene Ther. 2014. PMID: 24722357 Free PMC article.
-
Adenovirus-triggered innate signalling pathways.Eur J Microbiol Immunol (Bp). 2011 Dec;1(4):279-88. doi: 10.1556/EuJMI.1.2011.4.3. Epub 2011 Dec 23. Eur J Microbiol Immunol (Bp). 2011. PMID: 24516734 Free PMC article. Review.
-
Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells.Cancer Biol Ther. 2013 Nov;14(11):1039-49. doi: 10.4161/cbt.26110. Epub 2013 Aug 28. Cancer Biol Ther. 2013. PMID: 24025359 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources